AIRNA
Hyun Gyung Jang, PhD, currently serves as the Director of DMPK and Clinical Pharmacology at AIRNA since October 2024. Previously, Jang was a Principal Scientist at Entrada Therapeutics from February 2023 to October 2024 and held several positions at Wave Life Sciences from April 2016 to January 2023, including Director and Principal Scientist in DMPK, where responsibilities encompassed support for Nucleic Acid therapeutics related to genetic diseases. Jang's extensive experience in DMPK includes roles at ARIAD Pharmaceuticals, Idenix Pharmaceuticals, and Agios Pharmaceuticals, focusing on various aspects of drug metabolism and pharmacokinetics. Jang holds a PhD in Pharmaceutical Chemistry from The Hebrew University of Jerusalem, along with a Master of Science in Biochemistry and a Bachelor of Science in Chemistry from Konkuk University.
This person is not in any teams
AIRNA
AIRNA, a biotech company pioneering RNA editing therapeutics to restore the health of patients with rare and common diseases. AIRNA’s experienced team is aiming to advance a pipeline of RNA editing therapeutics driven by its powerful and flexible RNA editing platform, RESTORE+.